The below Parliamentary question was asked by Tristram Hunt on 2016-02-24.
To ask the Secretary of State for Education, on how many occasions a special adviser of her Department has accompanied a Minister on a foreign trip since 1 October 2015; and what the cost of that travel has been.
Nick Gibb
Special advisers have not accompanied any Ministers on an international visit since 1 October 2015.
The below Parliamentary question was asked by Anne Marie Morris on 2016-03-01.
To ask Mr Chancellor of the Exchequer, how much the Government has paid in fines to the EU since 2010.
Mr David Gauke
The United Kingdom has never incurred a financial penalty under Article 260 of the Treaty on the functioning of the European Union (or under the former Article 228 (ex Article 171) of the Treaty Establishing the European Community).
The below Parliamentary question was asked by Justin Madders on 2016-03-01.
To ask the Secretary of State for Health, if he will ensure that the conclusions of appraisals currently being undertaken by NICE are revisited in the light of the conclusions of the Accelerated Access Review: Interim Report, published October 2015.
Ben Gummer
The National Institute for Health and Care Excellence (NICE) is an independent body responsible for developing its guidance in line with its published methods and processes. It will be for NICE to consider the impact of any relevant recommendations from the Accelerated Access Review on its guidance – either published or in development.
The below Parliamentary question was asked by Justin Madders on 2016-03-01.
To ask the Secretary of State for Health, how many UK citizens have a European Health Insurance Card (EHIC); and how many such people have used their EHIC to obtain state provided healthcare in other EU countries in each of the last five years.
Alistair Burt
The United Kingdom European Health Insurance Card (EHIC) means that people living in the UK are able to travel to the European Economic Area (EEA) safe in the knowledge that they will be able to receive free or reduced cost healthcare should they need it.
There are currently 27,570,911 cards in circulation, as of January 2016. The number of cards granted since 2006, providing such cover is:
2014/15 – 5,414,977
2013/14 – 5,571,060
2012/13 – 5,240,608
2011/12 – 6,830,734
2010/11 – 5,703,895
2009/10 – 4,162,170
2008/09 – 4,269,023
2007/08 – 4,160,935
2006/07 – 5,163,121
Source: Business Services Authority
The Department does not hold information about on how many people have used their UK EHIC to obtain state provided healthcare in another EEA country in any 12 month period. This is because data on UK EHIC usage is recorded by individual treatment episode rather than the card holder.
The below Parliamentary question was asked by Justin Madders on 2016-03-01.
To ask the Secretary of State for Health, with reference to page 15 of the interim report of the Accelerated Access Review, published October 2014, what recent discussions he has had on the implementation of new models of pricing and reimbursing drugs; when he anticipates implementing such models; what discussions he has had with (a) his Department’s officials and (b) external organisations on the applicability of such models to drugs targeting the genetically validated target PCSK9; and if he will make a statement.
George Freeman
The Accelerated Access Review, chaired by Sir Hugh Taylor, will make recommendations to government on reforms to accelerate access for National Health Service patients to innovative medicines and medical technologies making our country the best place in the world to design, develop and deploy these products. The terms of the reference for the review focus on faster access to innovations, which may include drugs that target genetically validated targets such as PCSK9 and BCL2.
The below Parliamentary question was asked by Justin Madders on 2016-03-01.
To ask the Secretary of State for Health, pursuant to the Answer of 11 February 2016 to Question 26284, what steps NHS England has taken to deal with potential conflicts of interests in the support offered by Deloitte to the development of its clinical commissioning policies; and if he will make a statement.
Ben Gummer
Deloitte is contracted to provide consultancy and advice to NHS England in support of its policy development programme for commissioned specialised services.
Deloitte is acting in an advisory capacity only and all decisions and governance processes associated with the policy development and adoption process have been retained by NHS England.
Where there has been potential for commercial in confidence information, this data and any associated analysis has been handled by NHS England alone.
The below Parliamentary question was asked by Justin Madders on 2016-03-01.
To ask the Secretary of State for Health, pursuant to the Answer of 9 February 2016 to Question 25939, what proportion of the income from estimated Pharmaceutical Price Regulation Scheme payments for 2016-17 will be brought forward from estimated payments due in (a) 2017-18 and (b) 2018-19.
Ben Gummer
The Government announced in December 2015 that the Pharmaceutical Price Regulation Scheme (PPRS) payment percentage for the 2016 calendar year is 7.80%. This represents an increase of 2.64 percentage points as a result of the addendum to the PPRS agreed with the Association of the British Pharmaceutical Industry and published alongside the 2016 payment percentage. The income brought forward to 2016 as a result of this agreement will depend on a number of factors, including total branded medicine sales to the National Health Service over the course of the year.
The below Parliamentary question was asked by Justin Madders on 2016-03-01.
To ask the Secretary of State for Health, pursuant to the Answer of 11 February 2016 to Question 26284, on NHS England: Deloitte, what the overall value of the contract is.
Ben Gummer
Due to the need to safeguard commercial-in-confidence information, we are unable to provide this information, as to do so risks materially affecting NHS England’s ability to secure value for money in any subsequent procurement.
The below Parliamentary question was asked by Justin Madders on 2016-03-01.
To ask the Secretary of State for Health, with reference to page 24 of the interim report of the Accelerated Access Review, published in October 2015, what steps he is taking to ensure that drugs that target the genetically validated targets (a) PCSK9 and (b) BCL2 are introduced into routine NHS care; and if he will make a statement.
George Freeman
The Accelerated Access Review, chaired by Sir Hugh Taylor, will make recommendations to government on reforms to accelerate access for National Health Service patients to innovative medicines and medical technologies making our country the best place in the world to design, develop and deploy these products. The terms of the reference for the review focus on faster access to innovations, which may include drugs that target genetically validated targets such as PCSK9 and BCL2.
The below Parliamentary question was asked by Justin Madders on 2016-03-01.
To ask the Secretary of State for Health, how much the UK has received in grants and funding from the EU to fund research into cancer under (a) the EU’s seventh framework programme 2007-2013 and (b) the current Horizon 2020 programme.
Ben Gummer
The Department does not hold this information.